Aceclidine Brimonidine Composition for Presbyopia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for presbyopia often result in significant side effects such as diminished distance vision, blurred vision, pain, redness, impaired night driving, and risk of retinal detachment, and require invasive procedures or cycloplegic agents, with limited duration and efficacy.
Innovation Solution
A pharmaceutical composition comprising 0.3% to 2.0% w/v aceclidine and 0.07% to 0.15% w/v brimonidine, optionally with surfactants and viscosity agents, is administered to enhance near vision acuity and depth of focus without compromising distance vision or causing significant side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If general miotic agents (pilocarpine, carbachol, phospholine iodide) are used to induce pinhole pupil and extend depth of focus, then near vision is improved, but distance vision is compromised and side effects such as ciliary spasm, migraine-like brow pain, and blurred distance vision occur
Solution Approach 1:
The patent combines aceclidine (a muscarinic agonist) with brimonidine (an alpha-2 adrenergic agonist) in a single ophthalmic composition. This merging of two different drug mechanisms allows the aceclidine to induce pinhole pupil for improved near vision while the brimonidine concurrently reduces ciliary muscle contraction, thereby preventing ciliary spasm and associated side effects like brow pain and distance vision blur
Solution Approach 2:
Brimonidine acts as an intermediary agent that mediates between the desired effect of pinhole pupil induction and the unwanted side effects. By adding brimonidine to the composition, it intermediates the ciliary muscle response, reducing excessive contraction and preventing the harmful effects while allowing the aceclidine to maintain its pinhole pupil effect
2Measurement precision
If higher concentrations of miotic agents are used to achieve sufficient pinhole pupil diameter (2.0 mm or less), then depth of focus is extended, but ciliary muscle contraction increases causing migraine-like pain and blurred distance vision
Solution Approach 1:
The patent converts the harmful effect of ciliary muscle contraction into a beneficial outcome by using brimonidine to selectively reduce the excessive contraction while maintaining the pinhole pupil effect. The brimonidine transforms the harmful ciliary spasm into a controlled state where the pinhole pupil remains constricted for depth of focus extension without the painful side effects
3Object-generated harmful factors
If weaker concentrations of miotic agents are used to reduce side effects, then ciliary spasm and pain are reduced, but the pinhole pupil effect becomes marginal and near vision improvement is limited
Solution Approach 1:
The patent changes the parameters of the treatment by using a combination of two drugs at optimized concentrations rather than a single drug at variable concentrations. The aceclidine is used at concentrations that effectively induce pinhole pupil while the brimonidine is added at concentrations that specifically target and reduce ciliary muscle contraction, achieving both adequate near vision improvement and reduced side effects simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition improves near vision acuity and depth of focus with prolonged duration, reduced side effects, and eliminates the need for cycloplegic agents, providing enhanced visual acuity and comfort for presbyopic patients.
Implementation Method 1
These general miotics can induce a pinhole pupil at sufficient concentrations to achieve pupils below 2.0 mm and potentially extend depth of focus
Implementation Method 2
these agents trigger increased ciliary muscle contraction and induce accommodation of any remaining reserves, improving near vision at the expense of distance vision
Data Source
AI summary
The present invention is directed to compositions for and methods for the treatment of presbyopia comprising from about 0.3% to about 2.0% w/v aceclidine and from about 0.07% to about 0.15% w/v brimonidine.